Key Performance
More- Earnings Score: N/A
- Momentum Score: 63
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
Avalo Therapeutics priced an underwritten public offering of 19.73 million shares at $17.75 per share and 1.4 million pre-funded warrants, expected to raise approximately $375 million in gross proceeds. The company plans to use the funds to advance clinical development of its lead asset abdakibart, including Phase 3 topline data release, following positive Phase 2 results in hidradenitis suppurativa. The offering is expected to close on May 7, 2026.
05/05/2026, 11:33 PM • GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics, a clinical-stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, announced that management will participate in two investor conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25. The company's lead asset, AVTX-009, is currently in Phase 2 clinical trials for hidradenitis suppurativa.
02/04/2026, 7:00 AM • GlobeNewswire
A comprehensive analysis reveals a robust pipeline for hidradenitis suppurativa treatment, with 24+ companies developing 26+ therapies, focusing on innovative biologic and targeted approaches like IL-17 and JAK inhibitors to address significant unmet clinical needs.
10/23/2025, 1:00 PM • GlobeNewswire
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Merus NV shares jumped 38.2% in pre-market trading after Genmab announced plans to acquire the company for $8 billion in an all-cash deal, adding breakthrough therapy Petosemtamab to its late-stage pipeline.
09/29/2025, 5:07 AM • Benzinga
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
Avalo Therapeutics announced the appointment of Kevin R. Lind to its Board of Directors, bringing over 20 years of leadership experience in biotechnology and capital markets. Lind previously led Longboard Pharmaceuticals to a $2.6 billion acquisition and will support Avalo's development of AVTX-009 for hidradenitis suppurativa.
09/22/2025, 7:00 AM • GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics announced participation in three investor conferences in September 2025, highlighting their lead asset AVTX-009, a monoclonal antibody targeting IL-1β for treating inflammatory diseases.
08/27/2025, 7:00 AM • GlobeNewswire
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences to discuss its lead asset AVTX-009, a monoclonal antibody targeting inflammatory diseases.
06/23/2025, 7:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.